世界贸易组织近日发布的《2025世界贸易报告》预测，在正确的政策支持下，到2040年人工智能的 应用有望推动全球贸易增长近40%，全球GDP将增长12%至13%。这一预测不仅彰显了人工智能技术的 巨大潜力，更为全球贸易发展描绘了令人振奋的前景。 在当前全球经济复苏乏力、贸易增长动能不足的背景下，人工智能正在成为推动全球贸易转型升 级、实现可持续增长的重要力量，通过多重路径赋能全球贸易发展。 极大降低贸易成本。在传统国际贸易中，信息搜寻、合同签订、跨境支付、物流运输等环节都存在 大量交易成本，人工智能可以通过智能匹配、自动化流程、优化决策等显著提高贸易效率。相关研究表 明，智能报关系统可缩短70%的通关时间，人工智能驱动的供应链管理可降低20%至30%的物流成本。 推动建立开放、包容、非歧视的人工智能贸易政策环境。各国应避免采取不必要的贸易限制措施， 通过世贸组织等多边平台加强对话协调，制定人工智能相关产品的标准互认机制，降低贸易壁垒。同 时，在数据跨境流动、隐私保护、数字税收等关键问题上寻求国际共识，为人工智能赋能贸易创造可预 测的政策环境。 加强人工智能领域的能力建设和人才培养合作。发达国家应通过技术转让、 ...

Group 1: Company Overview and IPO Progress - Guangxi Tianyuan Biochemical Co., Ltd. (referred to as "Tianyuan Biochemical") has completed its IPO counseling report and is officially targeting the capital market with annual revenue exceeding 1.7 billion yuan [1] - The company, founded in 1994, focuses on three main business segments: pesticide formulations, medicinal fertilizers, and smart agricultural machinery [5] - The company signed a counseling agreement in April 2022 with Guohai Securities as the counseling institution, optimizing its equity structure during the counseling period [7] Group 2: Financial Performance and Concerns - The company has shown a continuous increase in net profit over three years, with figures of 162 million yuan in 2022, 229 million yuan in 2023, and 249 million yuan in 2024 [3] - However, there are concerns regarding a revenue decline in 2024 and a drop in product prices across the board, with a significant 36.5% decrease in herbicide prices from 39.63 yuan/kg in 2022 to 25.16 yuan/kg in 2024 [12][13] - The company distributed a total of 221 million yuan in dividends in the two years leading up to the IPO, raising questions about the rationale behind such distributions prior to seeking 630 million yuan in fundraising [15][26] Group 3: Sales Model and Risks - The company relies heavily on a distribution network, with over 95% of revenue coming from distributors from 2022 to 2024, which poses risks such as management control issues and potential channel loss [10][12] - The pricing control has been challenging, as evidenced by the continuous decline in average selling prices of all main products during the reporting period [12][13] Group 4: Research and Development (R&D) Challenges - The company's R&D expenditure rates were 2.53%, 2.71%, and 4.24% from 2022 to 2024, consistently below the industry average of 4.98%, 5.29%, and 5.18% [15][17] - The company has justified its lower R&D spending by citing the high output from its medicinal fertilizer products, but this "catch-up" approach to R&D may raise concerns about its long-term innovation capabilities [19] Group 5: Compliance and Regulatory Issues - The company faces potential compliance issues, including 11,400 square meters of unlicensed property, which could be classified as illegal construction [20] - There have been administrative penalties related to the sale of counterfeit pesticides and misrepresentation of product origins, highlighting vulnerabilities in production quality control and supply chain management [23][25]